Sector News

Boston Scientific picks up a fib player Apama in deal worth up to $300M

October 16, 2017
Life sciences

Boston Scientific closed its acquisition of Apama Medical, a developer of a radiofrequency balloon catheter for the treatment of atrial fibrillation. While the device maker forked over $175 million in cash up front, Apama stands to earn up to $125 million in milestone payments.

Apama will collect follow-on payments for achieving clinical and regulatory milestones from 2018 to 2020, according to a statement. Boston Sci announced the deal earlier this month.

Last November, Apama raised $13 million in series C financing. The Campbell, California-based startup is developing a catheter ablation system for a fib that combines the best of two major approaches used to treat the condition—single-point radiofrequency ablation and balloon catheter ablation.

Single-point RF ablation is used to treat multiple types of a fib, but the procedure takes a long time, while balloon catheter ablation is quicker but is limited to a few a fib types.

“The Apama RF Balloon Catheter System is an innovative solution that addresses the gaps in existing catheter ablation technologies,” said Dr. Amin Al-Ahmad of the Texas Cardiac Arrhythmia Institute, when Apama announced its series C round. “The multipoint RF system enables single shot, customizable ablation geometries for improved efficiency and versatility. In addition, built-in cameras enable real-time visualization that allows for enhanced navigation and feedback on electrode contact.”

Apama is the third company out of medtech incubator Shifamed to be acquired. The other two were Kalila Medical, snatched up by Abbott last year and Maya Medical, sold off to Covidien in 2012.

“Shifamed was formed out of my passion for engineering in the medical field and the ability to work alongside and enable others to develop innovative solutions that make a positive impact on patient lives,” said Amr Salahieh, who founded Shifamed in 2009. “We are thrilled to collaborate with companies like Boston Scientific that excel at bringing advanced solutions to the patients and care providers we serve.”

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.